Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

Prevision Policy Clips | Pfizer Will Present On Three Vaccine Candidates During February ACIP Meeting

February 21, 2023

“The Will” Vs. “The Wait”: CBER’s Marks, OTAT’s Bryan Give Differing Views Of Accelerated Approval For Gene Therapies

February 17, 2023

Emergent’s Narcan Nasal Spray Unanimously Supported For OTC Use; Set To Be First Nonprescription Opioid Reversal Agent – And First-Of-Its Kind FDA-Initiated Public Health Switch

February 17, 2023

Prevision Policy Clips | FDA Office Of Oncologic Diseases Deputy Director Slot Vacant After Julia Beaver Departs

February 17, 2023

FDA Gene Therapy Reorg: Industry Should Expect “A Year Or Two” For Staffing To Catch Up With Demand; Policy Plans Include “Platform,” Efforts Inspired By “Warp Speed,” RTOR And Orbis

February 16, 2023

FDA’s Califf Calls For Return To Large, Simple Trials Without “Useless Stuff” That Slows Development; Praises OCE’s “Project Pragmatica”

February 16, 2023

CMMI Drug Pricing Models: $2 Generics Ready To Go; Centralized Gene Therapy Contracts May Support SCD Launches; Can CMS Help Accelerated Approval?

February 16, 2023

Prevision Policy Clips | Moderna To Testify At Senate HELP Committee On COVID Vaccine Pricing Plans

February 16, 2023

FDA Advisory Committees Moving To In-Person Meetings: Califf Envisions Earlier, Big-Picture Topics For Discussion, Less “Gladiator”-Type Approval Votes

February 16, 2023

Prevision Policy Clips | Drug Pricing Demos Announced By HHS—But Implementation Timeline And Details Are Still TBD

February 15, 2023

CMS Considering New Approaches For Gene Therapy In Medicaid, But Not ASP Or “Protected Class” Changes; COO Blum Calls For Data On IRA Impact On Innovation

February 14, 2023

Prevision Policy Clips | CBER Listening Session On Cell/Gene Therapy Data Collection From RWE/Registries

February 14, 2023

Prevision Policy Clips | CBER Working On Warp Speed For Rare Diseases, Director Peter Marks

February 13, 2023

Project Orbis Update: 71 Orbis Approvals and Counting Since Program Began in 2019

February 12, 2023

GSK Jemperli Accelerated Approval In Rectal Cancer Is Possible With Tweaks To Proposed Plan, FDA Committee Says; Model For AA Plans?

February 10, 2023

USPTO/FDA Coordination On Patents: First Practical, Politically Palatable Lesson May Be For PTO To Adopt FDA Processes For Soliciting Patient Perspective

February 10, 2023

Medicare Inflation Rebate Implementation Plan Unveiled: Manufacturers Would Have 10 Days To Check Invoices For Errors Under Proposed Policy; CMS Expects First Invoices In 2025

February 10, 2023

Prevision Policy Clips | FDA Commissioner Robert Califf To Keynote Biopharma Congress On February 13; FDORA, Impacts Of The IRA

February 10, 2023

Pharma Patent/Competition Bills Return In Senate; Bipartisan Talks Continue On Scope Of FTC Authorities

February 9, 2023

FDA/Sponsor Communication To Be Subject Of House E&C Hearings; Advisory Committees, Inspections Among Other Questions For Califf During COVID Hearing

February 9, 2023

Prevision Policy Clips | FDA COVID “Direct-To-Final” Guidance Clean-Up: Agency Withdraws Propofol Re-Packaging Policy

February 9, 2023

Accelerated Approval For Gene Therapies: OTAT Town Hall Suggests Pathway Viable In Slowly Progressive Disease With Clear Natural History

February 8, 2023

“Project Pause”? FDA Cancer Center Launches Fewer New Projects In 2022 To Allow Time To Advance Existing Work

February 8, 2023

Prevision Policy Clips | President Biden Takes IRA Victory Lap During State Of The Union

February 8, 2023

GSK’s Jemperli ODAC May Be Public Test Case For Accelerated Approval Development Meetings; Committee To Discuss Novel Endpoints At IND Stage

February 7, 2023
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy